首页> 外文期刊>International Journal of Applied and Basic Medical Research >Performance characteristics of kidney injury molecule-1 in relation to creatinine, urea, and microalbuminuria in the diagnosis of kidney disease
【24h】

Performance characteristics of kidney injury molecule-1 in relation to creatinine, urea, and microalbuminuria in the diagnosis of kidney disease

机译:与肌酐,尿素和微量白蛋白尿有关的肾脏损伤分子-1在肾脏疾病诊断中的性能特征

获取原文
           

摘要

Context: The diagnosis and evaluation of impaired renal function remains a challenge owing to lack of reliable biomarker for assessment of kidney function. The existing panel of biomarkers currently displays several limitations, and recently kidney injury molecule-1 (KIM-1) has been suggested as a sensitive biomarker of renal function and proposed to enter clinical practice. Aims: This study was conducted to determine the diagnostic value of serum creatinine, urea, and microalbuminuria (MAU) in relation to the novel biomarker, KIM-1. Materials and Methods: Serum creatinine, urea, MAU, and KIM-1 were measured in forty individuals with and forty without kidney disease. Data were analyzed using multivariate methods of assessing diagnostic efficiency, test agreement, condition effects, and variability. Results: The area under the receiver-operator characteristic curve revealed a diagnostic advantage of creatinine (0.924 ± 0.0066) and urea (0.925 ± 0.0068) over MAU (0.880 ± 0.078) and KIM-1 (0.35 ± 0.124). Overall diagnostic efficiency was higher for creatinine and urea (89.5% and 90.9%, respectively), followed by MAU (85.7%) and then KIM-1 (56.3%). Logistic regression analysis showed that creatinine and urea (R2 = 0.75 and R2 = 0.72, respectively, PR2 = 0.64, PR2 = 0.046, P = 0.116). Further analysis of agreement showed that urea had an excellent agreement with creatinine (kappa r = 0.835, Pr = –0.198, P = 0.087) showing a poor agreement with creatinine. Conclusion: Our results indicate that elevated serum creatinine and urea above specific cutoff points reliably identifies patients with acute kidney injury or chronic kidney disease. However, more researches are warranted to further validate the diagnostic efficiency and application of MAU and for KIM-1 before its implementation in clinical practice.
机译:背景:由于缺乏可靠的评估肾功能的生物标志物,肾功能受损的诊断和评估仍然是一个挑战。现有的生物标志物组目前显示出一些局限性,并且最近已经提出了肾损伤分子1(KIM-1)作为肾功能的敏感生物标志物,并建议进入临床实践。目的:进行这项研究以确定血清肌酐,尿素和微量白蛋白尿(MAU)对新型生物标志物KIM-1的诊断价值。材料和方法:在40名患有和40名无肾脏疾病的个体中测量了血清肌酐,尿素,MAU和KIM-1。使用评估诊断效率,测试协议,条件影响和变异性的多变量方法分析数据。结果:接收者-操作者特征曲线下方的区域显示出肌酐(0.924±0.0066)和尿素(0.925±0.0068)的诊断优势优于MAU(0.880±0.078)和KIM-1(0.35±0.124)。肌酐和尿素的总体诊断效率更高(分别为89.5%和90.9%),其次是MAU(85.7%),然后是KIM-1(56.3%)。 Logistic回归分析显示,肌酐和尿素(R 2 = 0.75和R 2 = 0.72,PR 2 = 0.64,PR 2 = 0.046,P = 0.116)。对一致性的进一步分析表明,尿素与肌酐的一致性极好(k r = 0.835,Pr = –0.198,P = 0.087),与肌酐的一致性差。结论:我们的结果表明,血清肌酐和尿素水平高于特定的临界点,可以可靠地识别出急性肾损伤或慢性肾脏病患者。然而,在临床实践中,有更多的研究需要进一步验证MAU和KIM-1的诊断效率和应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号